On April 18th, Cerevel reported positive results from its Phase 3 TEMPO-3 trial for tavapadon, a D1/D5 receptor partial agonist aimed at treating Parkinson's disease.
GPCRs, as key signal transduction molecules on the cell surface, regulate various physiological processes and constitute one-third of the targets for clinical drug applications.
The challenge is finding how to effectively alleviate these symptoms while maintaining sufficient safety. Tavapadon has found a balance in addressing this issue.
In March, British pharmaceutical giant AstraZeneca announced its intention to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing innovative therapies for rare endocrine diseases.
The study reveals a structure-guided strategy for biased drug optimization and has led to the development of two biased agonist drug candidates targeting the APLNR receptor.
Bitopic ligands of GPCRs (G protein-coupled receptors) refer to a single chemical entity composed of two pharmacophoric groups covalently linked together.
On March 28th, the journal "Cell" published an online research paper titled "Flexible Scaffold-based Cheminformatics Approach for Polypharmacological Drug Design".
X4 Pharmaceuticals announced preliminary results from its Phase 2 trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without injected G-CSF in patients with idiopathic, cyclic, or congenital neutropenia.